Jun 06, 2019 - BioMarin's (BMRN) Vimizim gains an NMPA nod in China for addressing patients suffering Morquio A syndrome, an ultra-rare genetic condition.
May 29, 2019 - BioMarin (BMRN) announces significant reduction in annual bleed rate in phase III study evaluating gene therapy, valoctocogene roxaparvovec, in hemophilia A patients. However, investors are skeptical.
May 29, 2019 - Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
May 26, 2019 - There's at least one thing about these biotechs that the Oracle of Omaha should find especially appealing.
Apr 27, 2019 - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2019 Results Conference Call April 25, 2019 04:30 PM ET Company Participants Traci McCarty - VP, IR J.J. Bienaimé - Chairman and CEO Hank Fuchs - Presiden
Apr 26, 2019 - BioMarin's (BMRN) earnings and revenues surpass estimates in the first quarter.
Apr 26, 2019 - BMRN earnings call for the period ending March 31, 2019.
Apr 16, 2019 - Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Apr 03, 2019 - The grandaddy of gene-editing stocks recently provided an encouraging update, but it isn't the only experimental hemophilia therapy out there.
Mar 29, 2019 - Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.